Navigation Links
Verenium Corporation To Announce First Quarter 2012 Financial Results

SAN DIEGO, May 3, 2012 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced that it will release 2012 first quarter financial results on Thursday, May 10, 2012 after market close. In conjunction with the release, the Company will host a conference call with live webcast on Thursday, May 10 at 5:00 p.m. ET.

The call may be accessed by dialing 877-755-7422 (domestic) or 678-894-3067 (international) five minutes prior to start time and providing the passcode 56155577.  A link to the live webcast may be accessed by visiting the "Investors" section of the Company's website at  A replay of the event will be available on the Company's website approximately two hours after the call and will be archived for 30 days.

About Verenium
Verenium, an industrial biotechnology company, is a global leader in developing high-performance enzymes. Verenium's tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries, including the global food and fuel markets.  Read more at

Forward-Looking Statements
Statements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty.  These include, but are not limited to, statements related to Verenium's technology, products and product candidates, lines of business, operations, capabilities, commercialization activities, corporate partnerships, target markets, future financial performance, and near-term and longer-term growth and prospects.  Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements.  Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's strategic focus, technologies, products and product candidates, dependence on patents and proprietary rights,  protection and enforcement of its patents and proprietary rights, the commercial prospects of the industries in which Verenium operates and sells products, Verenium's dependence on manufacturing and/or license agreements,  its ability to achieve milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize its technologies and products (including by obtaining any required regulatory approvals) using Verenium's technologies, the timing for launching any commercial products and projects, the ability of Verenium and its collaborators to market and sell any products that it or they commercialize, the development or availability of competitive products or technologies, the future ability of Verenium to enter into and/or maintain collaboration and joint venture agreements and licenses, and risks and other uncertainties more fully described in Verenium's filings with the Securities and Exchange Commission, including, but not limited to, Verenium's annual report on Form 10-K for the year ended December 31, 2011 and any updates contained in its subsequently filed quarterly reports on Form 10-Q .  These forward-looking statements speak only as of the date hereof, and Verenium expressly disclaims any intent or obligation to update these forward-looking statements.


Sarah Carmody
Manager, Corporate Communications

SOURCE Verenium Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
2. Verenium Corporation to Present at the William Blair & Company 2008 Small-Cap Growth Stock Conference
3. Verenium Corporation to Announce Third Quarter 2008 Financial Results
4. Verenium Corporation to Speak at the Credit Suisse Alternative Energy Conference
5. Verenium Regains Compliance With Nasdaq Continued Listing Requirement
6. Verenium Announces First Commercial Cellulosic Ethanol Project
7. Verenium Announces Organizational Changes
8. Verenium Completes Amendment to 8% Senior Convertible Notes
9. BP and Verenium Announce Vercipia Biofuels to Advance the Commercialization of Cellulosic Ethanol
10. Verenium Announces Reverse Stock Split to Take Effect September 9
11. Verenium 1:12 Reverse Stock Split Takes Effect
Post Your Comments:
(Date:10/13/2015)... -- PharmaCyte Biotech, Inc. (OTCQB: PMCB) shares closed at $.1035, ... average with 1,308,352 shares being traded. PMCB shares have been ... low of $.072 in September, then bouncing back to current ... due diligence will show investors in PharmaCyte Biotech, Inc. information ... using the link below at no cost. ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... and assessment of organotypic 3D cell culture models, has launched a 14 ... in their patent-pending 3D InSightâ„¢ Human Liver Microtissues. The service streamlines toxicity ...
(Date:10/13/2015)... , ... October 13, 2015 , ... ... President. Steve joins as the Pistoia Alliance continues to drive to increase the ... non-profit Pistoia Alliance is focusing its vision and expanding its work in supporting ...
(Date:10/13/2015)... Oct. 13 2015 Research and Markets( ... & Europe Markets for Bone Morphogenetic Protein Growth Factor ... offering. --> --> ... the formation of bone after a fracture. In nature, ... in the formation of the skeleton. There are twenty ...
Breaking Biology Technology:
(Date:10/13/2015)... Feedzai , a data science company ... and minimize risk in the financial industry, announced a ... fraud prevention solution that gives merchants the ability to ... email address. The two companies will provide their mutual ... risk assessment with fraud risk scoring to streamline transaction ...
(Date:10/13/2015)... Dragon Capital Group Corp. (OTC: DRGV), a holding company ... announced today that its wholly owned subsidiary, Shanghai Yazheng Information ... Naked Eye 3D System for a period of one year. ... is expected to be completed in 2015. Management estimates the ... --> --> This Multi-Format Naked ...
(Date:10/13/2015)... DUBLIN , Oct. 7, 2015 Research ... of the "India Biometrics Authentication & Identification Market ... offering. --> --> ... from $823.46 million in 2014 to $2.06 billion in ... to 2020. India . ...
Breaking Biology News(10 mins):